INSULET CORP PODD

Insulet Corporation’s Omnipod franchise just printed another quarter of blockbuster growth-$761.7m in revenue, $91.1m in net income, and $122.1m in operating profit for the three months ending 31 March 2026-while quietly disclosing that a slice of its US sales came from a single related party to the tune of $148.5m. The 10-Q filing shows American Omnipod sales rose 28.3% to $515.6m, but the footnote reveals the contribution from that one customer, making the headline number look a little less organic. (source: Insulet 10-Q, https://www.sec.gov/Archives/edgar/data/1145197/000114519726000102/podd-20260331.htm)

The same document flags $89.7m in R&D spend and $24.3m in new factory equipment, because when your disposable medical device runs on a conveyor belt, the belt still needs fixing. Cash from operations clocked in at $113.8m, while inventories climbed $11.5m to $462.5m, underscoring how a high-growth medtech company still has to warehouse millions of pods before they reach patients. (source: Insulet 10-Q, https://www.sec.gov/Archives/edgar/data/1145197/000114519726000102/podd-20260331.htm)

Then came the 26 May 2026 press release: a voluntary medical device correction for specific lots of Omnipod, announced because ongoing product monitoring caught a manufacturing issue. The 8-K filing reads like a polite heads-up from a neighbour returning your lawnmower with a note saying it had ‘a bit of a wobble,’ yet the financials still show 30.1% constant-currency revenue growth in the same quarter. The recall isn’t disclosed as a material financial risk in the 10-Q, but it does remind investors that even the slickest insulin pump supply chain can’t escape the occasional factory gremlin. (source: Insulet 8-K and 10-Q, https://www.sec.gov/Archives/edgar/data/1145197/000114519726000132/podd-20260526.htm; https://www.sec.gov/Archives/edgar/data/1145197/000114519726000102/podd-20260331.htm)

Insulet’s Omnipod is a tubeless, waterproof insulin pump worn on the body, dispensing rapid-acting insulin through a thin cannula and controlled wirelessly by a handheld or smartphone controller. The platform competes with traditional pump-and-cannula systems and multiple daily injection regimens, targeting people with type 1 diabetes who want the flexibility of a wearable without the tubing. The product is cleared in the US and other markets, with revenue recognised at the point of sale to distributors and payers. (source: Insulet product description, inferred from filings and investor materials)

For the visually minded, the company’s investor site hosts the latest Omnipod imagery and technical specs, though the filings themselves don’t embed product shots-just the facts that the pumps exist, they’re recalled in specific lots, and the company is still shipping to a growing installed base. (source: Insulet investor relations, https://investors.insulet.com/)

The balance sheet shows $2.99bn in assets against $1.68bn in liabilities, with $1.30bn in shareholders’ equity, giving the company a solid foundation even as it navigates recalls and inventory bloat. Diluted EPS of $1.30 on 70.2m shares rounds out the headline numbers, but the footnotes matter more: one big customer, a factory hiccup, and an R&D bill that keeps growing even as the top line does. (source: Insulet 10-Q, https://www.sec.gov/Archives/edgar/data/1145197/000114519726000102/podd-20260331.htm)

If you’re chasing chart levels, the SEC rail doesn’t provide them; the filings give the fundamentals, the recall gives the operational risk, and the rest is noise. The company’s XBRL company facts feed and EDGAR index confirm the raw numbers but don’t chart them, so treat any price chatter as external to this file. (source: SEC companyfacts JSON and EDGAR index, https://data.sec.gov/api/xbrl/companyfacts/CIK0001145197.json; https://www.sec.gov/edgar/browse/?CIK=1145197)